S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
S&P 500   3,980.97 (+0.25%)
DOW   32,463.41 (+0.70%)
QQQ   308.55 (-0.75%)
AAPL   158.61 (-1.02%)
MSFT   276.25 (-1.54%)
META   202.22 (-1.84%)
GOOGL   102.44 (-2.85%)
AMZN   97.43 (-0.71%)
TSLA   192.56 (+1.13%)
NVDA   264.28 (-1.31%)
NIO   8.93 (-1.54%)
BABA   85.74 (-1.33%)
AMD   95.87 (-2.12%)
T   18.86 (+1.34%)
F   11.52 (+0.09%)
MU   59.70 (-2.39%)
CGC   1.89 (-0.53%)
GE   93.02 (+1.81%)
DIS   94.97 (+0.95%)
AMC   4.36 (-2.46%)
PYPL   73.49 (-0.53%)
PFE   40.31 (-0.20%)
NFLX   329.17 (+0.24%)
NASDAQ:BMRA

Biomerica - BMRA Stock Forecast, Price & News

$1.98
+0.06 (+3.13%)
(As of 03/24/2023 06:55 PM ET)
Add
Compare
Today's Range
$1.87
▼
$1.99
50-Day Range
$1.86
▼
$3.00
52-Week Range
$1.84
▼
$5.25
Volume
7,800 shs
Average Volume
37,816 shs
Market Capitalization
$33.28 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

BMRA stock logo

About Biomerica (NASDAQ:BMRA) Stock

Biomerica, Inc. engages in the development, manufacture, and marketing of medical diagnostic products designed for the early detection and monitoring of chronic diseases and medical conditions. The firm focuses on gastrointestinal diseases, food intolerances, diabetes, and certain esoteric tests. It operates through the following geographical segments: Europe, United States, Asia, South America, Middle East, and Other. The company was founded in September 1971 and is headquartered in Irvine, CA.

Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Stock News Headlines

March 8, 2023 | finance.yahoo.com
Biomerica announces the Launch of InFoods IBS as a Laboratory Developed Test (LDT); First patient samples have been processed
March 7, 2023 | finance.yahoo.com
Biomerica Announces Closing of $8 Million Underwritten Public Offering of Common Stock
March 27, 2023 | Weiss Ratings (Ad)
Urgent Warning
This was never meant for the general public. But it’s all there in black and white … A frightening plan that gives the Fed the power to track and even control your checking account, including ALL your financial transactions. A pilot test program is already underway. And it’s slated to launch at America’s largest banks as soon as May of this year! So, time to prepare is very short. Fortunately, there are a few key steps you can take to defend yourself …
March 3, 2023 | finance.yahoo.com
Biomerica Announces Pricing of $8 Million Underwritten Public Offering of Common Stock
March 2, 2023 | finance.yahoo.com
Biomerica Announces Proposed Underwritten Public Offering of Common Stock
February 20, 2023 | finance.yahoo.com
We're Keeping An Eye On Biomerica's (NASDAQ:BMRA) Cash Burn Rate
January 10, 2023 | finance.yahoo.com
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
January 10, 2023 | finance.yahoo.com
Biomerica Appoints Mayo Clinic Gastroenterologist, Dr. Brian E. Lacy, to the Company’s Scientific Advisory Board
March 27, 2023 | Behind the Markets (Ad)
Buy THIS stock before Taiwan is attacked
... If the United States goes to war with another nuclear armed superpower, this could have a devastating impact on your retirement portfolio. Now, even Taiwan's own foreign minister is saying that China is on the cusp of a full scale invasion. But the good news is, if China invades Taiwan, there is a way to protect yourself.
December 24, 2022 | seekingalpha.com
Biomerica: H.Pylori Announcements Important To Keep An Eye On, Reaffirm Hold
December 8, 2022 | finance.yahoo.com
Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE
December 1, 2022 | finance.yahoo.com
We Think Shareholders May Consider Being More Generous With Biomerica, Inc.'s (NASDAQ:BMRA) CEO Compensation Package
October 17, 2022 | finanznachrichten.de
Biomerica, Inc.: Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
October 14, 2022 | finance.yahoo.com
Sneakerheads Will Be Happy: Nike Is Ready to Penalize Accounts Reselling Its Products - Yahoo Finance
October 14, 2022 | seekingalpha.com
Avenue, IMARA lead healthcare gainers; Galecto, Travere among losers - Seeking Alpha
October 14, 2022 | marketwatch.com
Biomerica stock leaps as Walmart expands sales of Aware Breast Self Exam to its stores - MarketWatch
October 14, 2022 | finance.yahoo.com
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 - Yahoo Finance
October 13, 2022 | globenewswire.com
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022 - GlobeNewswire
October 13, 2022 | finance.yahoo.com
Biomerica Reports 30% Increase in Revenues for Fiscal Q1 2023 vs. Fiscal Q1 2022
October 11, 2022 | finance.yahoo.com
Those who invested in Biomerica (NASDAQ:BMRA) five years ago are up 39%
September 30, 2022 | it.tmcnet.com
Biomerica's Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
September 29, 2022 | benzinga.com
Thinking about buying stock in BigBear.ai, Bed Bath & Beyond, Atara Biotherapeutics, Stabilis Solutions, - Benzinga
September 29, 2022 | benzinga.com
Biomerica's Aware Breast Self Exam and EZ Detect Colon Disease Test Now Available On Amazon And Fulfilled - Benzinga
September 29, 2022 | finance.yahoo.com
Biomerica’s Aware® Breast Self Exam and EZ Detect™ Colon Disease Test Now Available on Amazon and Fulfilled by Amazon
September 26, 2022 | globenewswire.com
Blood Testing Market to hit USD 123 Billion by 2030, says Global Market Insights Inc. - GlobeNewswire
September 14, 2022 | globenewswire.com
LifeMD Expands Primary Care Platform's Diagnostic - GlobeNewswire
September 9, 2022 | seekingalpha.com
Biomerica: One To Watch Closely For The Future, But From The Sidelines For Now
See More Headlines
Receive BMRA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Biomerica and its competitors with MarketBeat's FREE daily newsletter.

BMRA Company Calendar

Last Earnings
1/13/2023
Today
3/27/2023
Next Earnings (Estimated)
4/13/2023
Fiscal Year End
5/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:BMRA
CUSIP
N/A
CIK
73290
Web
www.biomerica.com
Phone
(949) 645-2111
Fax
949-553-1231
Employees
66
Year Founded
1971

Profitability

EPS (Most Recent Fiscal Year)
($0.43)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-4,530,000.00
Net Margins
-34.58%
Pretax Margin
-34.48%
Return on Equity
-66.11%
Return on Assets
-44.58%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.59
Quick Ratio
3.42

Sales & Book Value

Annual Sales
$18.87 million
Price / Sales
1.76
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.65 per share
Price / Book
3.05

Miscellaneous

Outstanding Shares
16,810,000
Free Float
14,173,000
Market Cap
$33.28 million
Optionable
Not Optionable
Beta
-0.53

Social Links


Key Executives

  • Zackary S. Irani
    Chairman & Chief Executive Officer
  • Gary Lu
    Chief Financial & Accounting Officer
  • Robert Carlson
    Chief Commercial Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













BMRA Stock - Frequently Asked Questions

How have BMRA shares performed in 2023?

Biomerica's stock was trading at $3.35 at the start of the year. Since then, BMRA shares have decreased by 40.9% and is now trading at $1.98.
View the best growth stocks for 2023 here.

When is Biomerica's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, April 13th 2023.
View our BMRA earnings forecast.

How were Biomerica's earnings last quarter?

Biomerica, Inc. (NASDAQ:BMRA) announced its earnings results on Friday, January, 13th. The company reported ($0.12) earnings per share for the quarter. The company earned $1.48 million during the quarter. Biomerica had a negative net margin of 34.58% and a negative trailing twelve-month return on equity of 66.11%.

What other stocks do shareholders of Biomerica own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Biomerica investors own include Sorrento Therapeutics (SRNE), Pfizer (PFE), Johnson & Johnson (JNJ), Ampio Pharmaceuticals (AMPE), OPKO Health (OPK), TG Therapeutics (TGTX), Advanced Micro Devices (AMD), Co-Diagnostics (CODX), FuelCell Energy (FCEL) and Trevena (TRVN).

What is Biomerica's stock symbol?

Biomerica trades on the NASDAQ under the ticker symbol "BMRA."

Who are Biomerica's major shareholders?

Biomerica's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Point72 Asset Management L.P. (3.12%), Geode Capital Management LLC (0.67%), Russell Investments Group Ltd. (0.47%), Hollencrest Capital Management (0.37%), Simplex Trading LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Allen Barbieri, Catherine Coste, Mark A Sirgo and Zackary S Irani.
View institutional ownership trends.

How do I buy shares of Biomerica?

Shares of BMRA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Biomerica's stock price today?

One share of BMRA stock can currently be purchased for approximately $1.98.

How much money does Biomerica make?

Biomerica (NASDAQ:BMRA) has a market capitalization of $33.28 million and generates $18.87 million in revenue each year. The company earns $-4,530,000.00 in net income (profit) each year or ($0.43) on an earnings per share basis.

How can I contact Biomerica?

Biomerica's mailing address is 17571 Von Karman Avenue, Irvine CA, 92614. The official website for the company is www.biomerica.com. The company can be reached via phone at (949) 645-2111, via email at jnesbett@institutionalms.com, or via fax at 949-553-1231.

This page (NASDAQ:BMRA) was last updated on 3/27/2023 by MarketBeat.com Staff